Role of voiding and storage symptoms for the quality of life before and after treatment in men with voiding dysfunction

World Journal of Urology

Volumn 28, Issue 1, 2010, Pages 3-8

  Sountoulides, Petros ^a   van Dijk, Marleen M ^a   Wijkstra, Hessel ^a   de la Rosette, Jean J M C H ^a   Michel, Martin Christian ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Blocker; Benign prostatic hyperplasia; Quality of life; Transurethral microwave thermotherapy; Transurethral resection of the prostate; Voiding dysfunction

Indexed keywords

AGED; ARTICLE; HUMAN; MALE; MICTURITION DISORDER; MIDDLE AGED; PATHOPHYSIOLOGY; PROSTATE HYPERTROPHY; QUALITY OF LIFE; RETROSPECTIVE STUDY;

AGED; HUMANS; MALE; MIDDLE AGED; PROSTATIC HYPERPLASIA; QUALITY OF LIFE; RETROSPECTIVE STUDIES; URINATION DISORDERS;

EID: 75849125651     PISSN: 07244983     EISSN: 14338726     Source Type: Journal    
DOI: 10.1007/s00345-009-0480-3     Document Type: Article

References (27)

1. Welch G, Kawachi I, Barry MJ et al (1998) Distinction between symptoms of voiding and filling in benign prostatic hyperplasia: findings from the health professionals follow-up study. Urology 51: 422-427.
2. Kaplan SA, Roehrborn CG, Chapple CR et al (2009) Implications of recent epidemiology studies for the clinical management of lower urinary tract symptoms. BJU Int 103(Suppl 3): 48-57.
3. Donovan JL (2000) The measurement of symptoms, quality of life and sexual function. BJU Int 85(Suppl 1): 10-19.
4. Engström G, Henningsohn L, Walker-Engström M-L et al (2006) Impact on quality of life of different lower urinary tract symptoms in men measured by the Short Form 36 SF 36 questionnaire. Scand J Urol Nephrol 40: 485-494.
5. Tubaro A, La Vecchia C (2004) The relation of lower urinary tract symptoms with life-style factors and objective measures of benign prostatic enlargement and obstruction: an Italian survey. Eur Urol 45: 767-772.
6. Robertson C, Link CL, Onel E et al (2007) The impact of lower urinary tract symptoms and comorbidities on quality of life: the BACH and UREPIK studies. BJU Int 99: 347-354.
7. Peters TJ, Donovan JL, Kay HE et al (1997) The International Continence Society "benign prostatic hyperplasia" study: the bothersomeness of urinary symptoms. J Urol 157: 885-889.
8. Yoshimura K, Arai Y, Ichioka K et al (2002) Symptom-specific quality of life in patients with benign prostatic hyperplasia. Int J Urol 9: 485-490.
9. Coyne KS, Wein AJ, Tubaro A et al (2009) The burden of lower urinary tract symptoms: evaluating the effects of LUTS on health-related quality of life, anxiety and depression: EpiLUTS. BJU Int 103(Suppl 3): 4-11.
10. Sexton CC, Coyne KS, Kopp ZS et al (2009) The overlap of storage, voiding and postmicturition symptoms and implications for treatment seeking in the USA, UK and Sweden: EpiLUTS. BJU Int 103(Suppl 3): 12-23.
11. Salinas-Sanchez AS, Hernandez-Millan I, Lorenzo-Romero JG et al (2001) Quality of life of patients on the waiting list for benign prostatic hyperplasia surgery. Quality Life Res 10: 543-553.
12. Araki I, Tsuchida T, Nomura T et al (2008) Differential impact of lower urinary tract symptoms on generic and disease-specific quality of life in men and women. Urol Int 81: 60-65.
13. Marklund-Bau H, Edell-Gustafsson U, Spangberg A (2007) Bothersome urinary symptoms and disease-specific quality of life in patients with benign prostatic obstruction. Scand J Urol Nephrol 41: 32-41.
14. Batista-Miranda JE, De la Cruz Diez M, Arano Betran P et al (2001) Quality-of-life assessment in patients with benign prostatic hyperplasia. Effects of various interventions. Pharmacoeconomics 19: 1079-1090.
15. Lepor H, Auerbach S, Puras-Baez A et al (1992) A randomized, placebo-controlled multicenter study of the efficacy and safety of terazosin in the treatment of benign prostatic hyperplasia. J Urol 148: 1467-1474.
16. Fabricius PG, Hannaford JM (1992) Placebo-controlled study of terazosin in the treatment of benign prostatic hyperplasia with 2-year follow up. Urology 70(Suppl 1): 10-16.
17. Chapple CR, Wyndaele JJ, Nordling J et al (1996) Tamsulosin, the first prostate-selective α1A-adrenoceptor antagonist. A meta-analysis of two randomized, placebo-controlled multicentre studies in patients with benign prostatic obstruction (symptomatic BPH). Eur Urol 29: 155-167.
18. Lee E, Lee C (1997) Clinical comparison of selective and non-selective α1A-adrenoreceptor antagonists in benign prostatic hyperplasia: studies on tamsulosin in a fixed dose and terazosin in increasing doses. Br J Urol 80: 606-611.
19. Lepor H (1998) Phase III multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasia. Urology 51: 892-900.
20. Kirby RS, Andersen M, Gratzke P et al (2001) A combined analysis of double-blind trials of the efficacy and tolerability of doxazosin-gastrointestinal therapeutic system, doxazosin standard and placebo in patients with benign prostatic hyperplasia. BJU Int 87: 192-200.
21. Michel MC, Flannery MT, Narayan P (2001) Worldwide experience with alfuzosin and tamsulosin. Urology 58: 508-516.
22. Roehrborn C, van Kerrebroeck P, Nordling J (2003) Safety and efficacy of alfuzosin 10 mg once-daily in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies. BJU Int 92: 257-261.
23. Djavan B, Milani S, Davies J et al (2005) The impact of tamsulosin oral controlled absorption system (OCAS) on nocturia and the quality of sleep: preliminary results of a pilot study. Eur Urol Suppl 4: 61-68.
24. Wasson JH, Reda DJ, Bruskewitz RC et al (1995) A comparison of transurethral surgery with watchful waiting for moderate symptoms of benign prostatic hyperplasia. New Engl J Med 332: 75-79.
25. Yalla SV, Sullivan MP, Lecamwasam HS et al (1995) Correlation of American Urological Association symptom index with obstructive and nonobstructive prostatism. J Urol 153: 674-680.
26. NRjr Netto, D'Ancona CAL, de Lima ML (1996) Correlation between the International Prostatic Symptom Score and a pressure-flow study in the evaluation of symptomatic benign prostatic hyperplasia. J Urol 155: 200-202.
27. Lee K-S, Lee HW, Han DH (2008) Does anticholinergic medication have a role in treating men with overactive bladder and benign prostatic hyperplasia? Naunyn-Schmiedeberg's Arch Pharmacol 377: 491-501.